Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP442631.RAdMVxeCIvraPOJ2ad-fyQfWKfmLozG9VvTamjLtnE7HQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP442631.RAdMVxeCIvraPOJ2ad-fyQfWKfmLozG9VvTamjLtnE7HQ130_assertion type Assertion NP442631.RAdMVxeCIvraPOJ2ad-fyQfWKfmLozG9VvTamjLtnE7HQ130_head.
- NP442631.RAdMVxeCIvraPOJ2ad-fyQfWKfmLozG9VvTamjLtnE7HQ130_assertion description "[Even more, molecular markers such as MLL partial tandem duplications (MLL-PTD) or FLT3 length mutations (FLT3-LM) were found to characterize specific subtypes of AML and completed the genetic marker profile.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP442631.RAdMVxeCIvraPOJ2ad-fyQfWKfmLozG9VvTamjLtnE7HQ130_provenance.
- NP442631.RAdMVxeCIvraPOJ2ad-fyQfWKfmLozG9VvTamjLtnE7HQ130_assertion evidence source_evidence_literature NP442631.RAdMVxeCIvraPOJ2ad-fyQfWKfmLozG9VvTamjLtnE7HQ130_provenance.
- NP442631.RAdMVxeCIvraPOJ2ad-fyQfWKfmLozG9VvTamjLtnE7HQ130_assertion SIO_000772 15124693 NP442631.RAdMVxeCIvraPOJ2ad-fyQfWKfmLozG9VvTamjLtnE7HQ130_provenance.
- NP442631.RAdMVxeCIvraPOJ2ad-fyQfWKfmLozG9VvTamjLtnE7HQ130_assertion wasDerivedFrom befree-2016 NP442631.RAdMVxeCIvraPOJ2ad-fyQfWKfmLozG9VvTamjLtnE7HQ130_provenance.
- NP442631.RAdMVxeCIvraPOJ2ad-fyQfWKfmLozG9VvTamjLtnE7HQ130_assertion wasGeneratedBy ECO_0000203 NP442631.RAdMVxeCIvraPOJ2ad-fyQfWKfmLozG9VvTamjLtnE7HQ130_provenance.